These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Camptothecins: new enthusiasm for an old drug. Rowe PM Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402 [No Abstract] [Full Text] [Related]
4. Are there any better camptothecins than the ones we have? Takimoto CH Clin Adv Hematol Oncol; 2003 Oct; 1(10):578-9, 600. PubMed ID: 16258452 [No Abstract] [Full Text] [Related]
5. Topoisomerase I inhibitors: topotecan and irenotecan. Creemers GJ; Lund B; Verweij J Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429 [No Abstract] [Full Text] [Related]
12. Schedule-dependent efficacy of camptothecins in models of human cancer. Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512 [No Abstract] [Full Text] [Related]
13. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. de Jonge MJ; Sparreboom A; Verweij J Cancer Treat Rev; 1998 Jun; 24(3):205-20. PubMed ID: 9767735 [No Abstract] [Full Text] [Related]
14. Current perspectives on camptothecins in cancer treatment. Dancey J; Eisenhauer EA Br J Cancer; 1996 Aug; 74(3):327-38. PubMed ID: 8695345 [TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical trials of topoisomerase inhibitors. Saijo N Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928 [TBL] [Abstract][Full Text] [Related]
16. Novel camptothecin derivatives. Legarza K; Yang LX In Vivo; 2005; 19(1):283-92. PubMed ID: 15796188 [TBL] [Abstract][Full Text] [Related]